BEL 20 Nov '19 (BEX19)
Seasonal Chart
Price Performance
See MorePeriod | Period Low | Period High | Performance | |
---|---|---|---|---|
1-Month | 3,740.00 +3.80% on 10/23/19 | | 3,891.50 -0.24% on 11/12/19 | +134.12 (+3.58%) since 10/15/19 |
Most Recent Stories
More NewsThe U.S. stock market is witnessing heightened volatility, setting the stage for volatility-linked investment strategies to potentially amplify the ongoing sell-off. The S&P 500 has receded from its peak...
I joined Michelle Rook on Agweb's Markets Now earlier today to discuss the soybean, corn, and wheat markets. We also chatted about the U.S. dollar, oil, the stock market, and cattle prices.
The U.S. job market exhibits unwavering strength as weekly jobless claims hold steady, hinting at a robust economic backdrop that could influence the Federal Reserve's monetary policy decisions. According...
The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.46%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.71%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.31%. US stock indexes this morning...
Income investors looking for more frequent dividend payments should consider monthly dividend stocks.
Blackstone (BX), the behemoth in private equity, delivered a modest rise in its first-quarter earnings, underpinned by an uptick in fee-related earnings despite a downtrend in profits from asset sales....
In the big picture, stocks are expensive and bonds are cheap
The S&P 500 Index ($SPX ) (SPY ) this morning is down -0.14%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.33%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.43%. US stock indexes this...
This software stock dropped sharply in March after a disappointing revenue forecast, but analysts have upgraded the shares from a consensus rating of 'Moderate Buy' to 'Strong Buy' in recent months.
Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.